{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:33:55Z","timestamp":1792596835794,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Acetylcholinesterase inhibitors (AChEIs) and memantine are currently the only anti-dementia drugs (ADDs) approved for treating Alzheimer\u2019s disease (AD) in Italy. This nationwide study aims to characterize dementia drug utilization in a population &gt; 65 years, during 2018\u20132020.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Different administrative healthcare databases were queried to collect both aggregate and individual data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>ADD consumption remained stable throughout the study period (~ 9 DDD\/1000 inhabitants per day). AChEI consumption was over 5 DDD\/1000 inhabitants per day. Memantine consumption was nearly 4 DDD\/1000 inhabitants per day, representing 40% of ADD consumption. The prevalence of use of memantine represented nearly half of ADD consumption, substantially unchanged over the 3 years. Comparing the AD prevalence with the prevalence of ADDs use, the gap becomes wider as age increases. In 2019, the proportion of private purchases of ADDs was 38%, mostly represented by donepezil and rivastigmine. In 2020, memantine was the only ADD with an increase in consumption (\u0394% 19\u201320, 1.3%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>To our knowledge, this study represents the first attempt to investigate the ADD prescription pattern in Italy with a Public Health approach. In 2019, the proportion of ADD private purchases point out several issues concerning the reimbursability of ADDs. From a regulatory perspective, ADDs can be reimbursed by the National Health System only to patients diagnosed with AD; therefore, the off-label use of ADDs in patients with mild cognitive impairment may partially explain this phenomenon. The study extends knowledge on the use of ADDs, providing comparisons with studies from other countries that investigate the prescription pattern of ADDs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10072-022-06586-8","type":"journal-article","created":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T07:03:45Z","timestamp":1672729425000},"page":"1587-1595","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Anti-dementia drugs: a descriptive study of the prescription pattern in Italy"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5676-1595","authenticated-orcid":false,"given":"Ilaria","family":"Ippoliti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3949-3127","authenticated-orcid":false,"given":"Antonio","family":"Ancidoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3416-6714","authenticated-orcid":false,"given":"Roberto","family":"Da Cas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pierantozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2817-3758","authenticated-orcid":false,"given":"Nicola","family":"Vanacore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6889-8484","authenticated-orcid":false,"given":"Francesco","family":"Trotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,3]]},"reference":[{"key":"6586_CR1","unstructured":"Global action plan on the public health response to dementia 2017\u20132025. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO"},{"key":"6586_CR2","unstructured":"The Medicines Utilization Monitoring Centre. National Report on Medicines use in Italy. Year 2020. Rome: Italian Medicines Agency, 2021"},{"issue":"3","key":"6586_CR3","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/archneur.56.3.303","volume":"56","author":"RC Petersen","year":"1999","unstructured":"Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56(3):303\u2013308. https:\/\/doi.org\/10.1001\/archneur.56.3.303","journal-title":"Arch Neurol"},{"issue":"1","key":"6586_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1017\/s1092852900016151","volume":"13","author":"RC Petersen","year":"2008","unstructured":"Petersen RC, Negash S (2008) Mild cognitive impairment: an overview. CNS Spectr 13(1):45\u201353. https:\/\/doi.org\/10.1017\/s1092852900016151","journal-title":"CNS Spectr"},{"issue":"4","key":"6586_CR5","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.3233\/JAD-180416","volume":"66","author":"I Bacigalupo","year":"2018","unstructured":"Bacigalupo I, Mayer F, Lacorte E, Di Pucchio A, Marzolini F, Canevelli M, Di Fiandra T, Vanacore N (2018) A systematic review and meta-analysis on the prevalence of dementia in Europe: estimates from the highest-quality studies adopting the DSM IV diagnostic criteria. J Alzheimers Dis 66(4):1471\u20131481. https:\/\/doi.org\/10.3233\/JAD-180416","journal-title":"J Alzheimers Dis"},{"key":"6586_CR6","doi-asserted-by":"publisher","unstructured":"Sachdev PS, Lipnicki DM, Kochan NA, Crawford JD, Thalamuthu A, Andrews G, Brayne C, Matthews FE, Stephan BC, Lipton RB, Katz MJ, Ritchie K, Carri\u00e8re I, Ancelin ML, Lam LC, Wong CH, Fung AW, Guaita A, Vaccaro R, Davin A, \u2026 Cohort Studies of Memory in an International Consortium (COSMIC) (2015) The prevalence of mild cognitive impairment in diverse geographical and ethnocultural regions: the COSMIC Collaboration. PloS one 10(11):e0142388. https:\/\/doi.org\/10.1371\/journal.pone.0142388","DOI":"10.1371\/journal.pone.0142388"},{"key":"6586_CR7","unstructured":"http:\/\/www.alzheimer-aima.it\/img\/iniziative\/Aima-Censis-24-febbraio_Sintesi-dei-risultati.pdf. Published February 2016. Accessed February 13, 2022"},{"key":"6586_CR8","unstructured":"https:\/\/www.aifa.gov.it\/nota-85. Agenzia Italiana del farmaco. Nota 85 erogazione a carico del servizio sanitario nazionale dei farmaci rivastigmina,\u00a0memantina,\u00a0galantamina,\u00a0donepezil. Accessed May 23, 2022"},{"key":"6586_CR9","doi-asserted-by":"publisher","unstructured":"Birks JS. Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD005593. https:\/\/doi.org\/10.1002\/14651858.CD005593. Accessed 14 February 2022","DOI":"10.1002\/14651858.CD005593"},{"issue":"17","key":"6586_CR10","doi-asserted-by":"publisher","first-page":"e2220","DOI":"10.1212\/WNL.0000000000011832","volume":"96","author":"H Xu","year":"2021","unstructured":"Xu H, Garcia-Ptacek S, J\u00f6nsson L, Wimo A, Nordstr\u00f6m P, Eriksdotter M (2021) Long-term effects of cholinesterase inhibitors on cognitive decline and mortality. Neurology 96(17):e2220\u2013e2230. https:\/\/doi.org\/10.1212\/WNL.0000000000011832","journal-title":"Neurology"},{"issue":"2","key":"6586_CR11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3233\/JAD-190546","volume":"71","author":"S Matsunaga","year":"2019","unstructured":"Matsunaga S, Fujishiro H, Takechi H (2019) Efficacy and safety of cholinesterase inhibitors for mild cognitive impairment: a systematic review and meta-analysis. J Alzheimers Dis 71(2):513\u2013523. https:\/\/doi.org\/10.3233\/JAD-190546","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"6586_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040338","volume":"4","author":"R Raschetti","year":"2007","unstructured":"Raschetti R, Albanese E, Vanacore N, Maggini M (2007) Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 4(11):e338. https:\/\/doi.org\/10.1371\/journal.pmed.0040338","journal-title":"PLoS Med"},{"issue":"4","key":"6586_CR13","doi-asserted-by":"publisher","first-page":"E419","DOI":"10.9778\/cmajo.20150057","volume":"3","author":"D Fitzpatrick-Lewis","year":"2015","unstructured":"Fitzpatrick-Lewis D, Warren R, Ali MU, Sherifali D, Raina P (2015) Treatment for mild cognitive impairment: a systematic review and meta-analysis. CMAJ Open 3(4):E419\u2013E427. https:\/\/doi.org\/10.9778\/cmajo.20150057","journal-title":"CMAJ Open"},{"issue":"2","key":"6586_CR14","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/0269881116680924","volume":"31","author":"JT O'Brien","year":"2017","unstructured":"O\u2019Brien JT, Holmes C, Jones M, Jones R, Livingston G, McKeith I, Mittler P, Passmore P, Ritchie C, Robinson L, Sampson EL, Taylor JP, Thomas A, Burns A (2017) Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol (Oxford, England) 31(2):147\u2013168. https:\/\/doi.org\/10.1177\/0269881116680924","journal-title":"J Psychopharmacol (Oxford, England)"},{"issue":"2","key":"6586_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S1474-4422(19)30480-6","volume":"19","author":"L Schneider","year":"2020","unstructured":"Schneider L (2020) A resurrection of aducanumab for Alzheimer\u2019s disease. Lancet Neurol 19(2):111\u2013112. https:\/\/doi.org\/10.1016\/S1474-4422(19)30480-6","journal-title":"Lancet Neurol"},{"issue":"2","key":"6586_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1001\/jamaneurol.2020.4478","volume":"78","author":"ES Musiek","year":"2021","unstructured":"Musiek ES, Morris JC (2021) Possible consequences of the approval of a disease-modifying therapy for Alzheimer disease. JAMA Neurol 78(2):141\u2013142. https:\/\/doi.org\/10.1001\/jamaneurol.2020.4478","journal-title":"JAMA Neurol"},{"key":"6586_CR17","unstructured":"https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/aducanumab-marketed-aduhelm-information. Published June 2021. Accessed February 14, 2022."},{"key":"6586_CR18","unstructured":"https:\/\/www.fda.gov\/media\/143502\/download. Published November 6, 2020. Accessed February 14, 2022."},{"key":"6586_CR19","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/withdrawn-applications\/aduhelm. Published April, 22, 2022. Accessed May 23, 2022."},{"issue":"1","key":"6586_CR20","doi-asserted-by":"publisher","first-page":"e12014","DOI":"10.1002\/trc2.12014","volume":"6","author":"R Wurm","year":"2020","unstructured":"Wurm R, Stamm T, Reichardt B, Schwarz F, Parvizi T, Silvaieh S, K\u00f6nig T, Cetin H, St\u00f6gmann E (2020) Prescription patterns of antidementives in a high income country: a pharmacoepidemiologic study. Alzheimers Dementia (NY) 6(1):e12014. https:\/\/doi.org\/10.1002\/trc2.12014","journal-title":"Alzheimers Dementia (NY)"},{"issue":"2","key":"6586_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","volume":"15","author":"F Panza","year":"2019","unstructured":"Panza F, Lozupone M, Logroscino G, Imbimbo BP (2019) A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease. Nat Rev Neurol 15(2):73\u201388. https:\/\/doi.org\/10.1038\/s41582-018-0116-6","journal-title":"Nat Rev Neurol"},{"key":"6586_CR22","doi-asserted-by":"publisher","first-page":"101339","DOI":"10.1016\/j.arr.2021.101339","volume":"68","author":"KI Avgerinos","year":"2021","unstructured":"Avgerinos KI, Ferrucci L, Kapogiannis D (2021) Effects of monoclonal antibodies against amyloid-\u03b2 on clinical and biomarker outcomes and adverse event risks: a systematic review and meta-analysis of phase III RCTs in Alzheimer\u2019s disease. Ageing Res Rev 68:101339. https:\/\/doi.org\/10.1016\/j.arr.2021.101339","journal-title":"Ageing Res Rev"},{"issue":"1","key":"6586_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3233\/JAD-220046","volume":"87","author":"E Lacorte","year":"2022","unstructured":"Lacorte E, Ancidoni A, Zaccaria V, Remoli G, Tariciotti L, Bellomo G, Sciancalepore F, Corbo M, Lombardo FL, Bacigalupo I, Canevelli M, Piscopo P, Vanacore N (2022) Safety and efficacy of monoclonal antibodies for Alzheimer\u2019s disease: a systematic review and meta-analysis of published and unpublished clinical trials. J Alzheimers Dis 87(1):101\u2013129. https:\/\/doi.org\/10.3233\/JAD-220046","journal-title":"J Alzheimers Dis"},{"key":"6586_CR24","unstructured":"https:\/\/www.whocc.no\/atc_ddd_index\/2021. World Health Organization. Anatomical Therapeutic Chemical (ATC) Classification. Accessed February, 16, 2022"},{"issue":"2","key":"6586_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1600-0404.2005.00444.x","volume":"112","author":"G Tognoni","year":"2005","unstructured":"Tognoni G, Ceravolo R, Nucciarone B, Bianchi F, Dell\u2019Agnello G, Ghicopulos I, Siciliano G, Murri L (2005) From mild cognitive impairment to dementia: a prevalence study in a district of Tuscany, Italy. Acta Neurol Scand 112(2):65\u201371. https:\/\/doi.org\/10.1111\/j.1600-0404.2005.00444.x","journal-title":"Acta Neurol Scand"},{"issue":"5\u20136","key":"6586_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000348408","volume":"35","author":"K Johnell","year":"2013","unstructured":"Johnell K, Religa D, Eriksdotter M (2013) Differences in drug therapy between dementia disorders in the Swedish dementia registry: a nationwide study of over 7,000 patients. Dement Geriatr Cogn Disord 35(5\u20136):239\u2013248. https:\/\/doi.org\/10.1159\/000348408","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"3","key":"6586_CR27","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3233\/JAD-180382","volume":"64","author":"J Bohlken","year":"2018","unstructured":"Bohlken J, Jacob L, van den Bussche H, Kostev K (2018) The influence of polypharmacy on the initiation of anti-dementia therapy in Germany. J Alzheimers Dis 64(3):827\u2013833. https:\/\/doi.org\/10.3233\/JAD-180382","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"6586_CR28","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s12603-020-1389-1","volume":"24","author":"A Bianchetti","year":"2020","unstructured":"Bianchetti A, Rozzini R, Guerini F, Boffelli S, Ranieri P, Minelli G, Bianchetti L, Trabucchi M (2020) Clinical presentation of COVID-19 in dementia patients. J Nutr Health Aging 24(6):560\u2013562. https:\/\/doi.org\/10.1007\/s12603-020-1389-1","journal-title":"J Nutr Health Aging"},{"issue":"9","key":"6586_CR29","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1007\/s10072-020-04541-z","volume":"41","author":"JM Hwang","year":"2020","unstructured":"Hwang JM, Kim JH, Park JS, Chang MC, Park D (2020) Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study. Neurol Sci 41(9):2317\u20132324. https:\/\/doi.org\/10.1007\/s10072-020-04541-z","journal-title":"Neurol Sci"},{"issue":"1","key":"6586_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1345\/aph.1K372","volume":"42","author":"ID Maidment","year":"2008","unstructured":"Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL (2008) Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother 42(1):32\u201338. https:\/\/doi.org\/10.1345\/aph.1K372","journal-title":"Ann Pharmacother"},{"issue":"3","key":"6586_CR31","first-page":"CD003154","volume":"3","author":"R McShane","year":"2019","unstructured":"McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE et al (2019) Memantine for dementia. Cochrane Database Syst Rev 3(3):CD003154","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"6586_CR32","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jalz.2012.01.002","volume":"9","author":"SD Rountree","year":"2013","unstructured":"Rountree SD, Atri A, Lopez OL, Doody RS (2013) Effectiveness of antidementia drugs in delaying Alzheimer\u2019s disease progression. Alzheimers Dement 9(3):338\u2013345. https:\/\/doi.org\/10.1016\/j.jalz.2012.01.002","journal-title":"Alzheimers Dement"},{"key":"6586_CR33","unstructured":"Dementia: assessment, management and support for people living with dementia and their carers NICE guideline [NG97] Published: 20 June 2018.\u00a0https:\/\/www.nice.org.uk\/guidance\/ng97.\u00a0Accessed 26 June 2022"},{"issue":"4","key":"6586_CR34","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.3233\/JAD-210634","volume":"83","author":"M Canevelli","year":"2021","unstructured":"Canevelli M, Di Pucchio A, Marzolini F, Mayer F, Massari M, Salvi E, Palazzesi I, Lacorte E, Bacigalupo I, Di Fiandra T, Vanacore N (2021) A national survey of centers for cognitive disorders and dementias in Italy. J Alzheimers Dis 83(4):1849\u20131857. https:\/\/doi.org\/10.3233\/JAD-210634","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"6586_CR35","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s11357-021-00470-7","volume":"44","author":"N Bal\u00e1zs","year":"2022","unstructured":"Bal\u00e1zs N, Bereczki D, Ajtay A, Oberfrank F, Kov\u00e1cs T (2022) Cholinesterase inhibitors for the treatment of dementia: real-life data in Hungary. Geroscience 44(1):253\u2013263. https:\/\/doi.org\/10.1007\/s11357-021-00470-7","journal-title":"Geroscience"},{"issue":"1","key":"6586_CR36","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1186\/s12913-016-1741-7","volume":"16","author":"G Bruti","year":"2016","unstructured":"Bruti G, Cavallucci E, Mancini M, Bitossi A, Baldereschi M, Sorbi S (2016) A systematic review of the quality of studies on dementia prevalence in Italy. BMC Health Serv Res 16(1):507. https:\/\/doi.org\/10.1186\/s12913-016-1741-7","journal-title":"BMC Health Serv Res"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06586-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-022-06586-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06586-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:03:46Z","timestamp":1681430626000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-022-06586-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,3]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["6586"],"URL":"https:\/\/doi.org\/10.1007\/s10072-022-06586-8","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,3]]},"assertion":[{"value":"28 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}